Nature Reviews Gastroenterology &Hepatology最新文献

Towards a reference cell atlas of liver diversity over the human lifespan. 迈向人类一生中肝脏多样性的参考细胞图谱。

IF 65.1 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-10-13 DOI: 10.1038/s41575-025-01114-3

Sarah A Taylor,Gary D Bader,Sonya MacParland,Alan C Mullen,Tallulah Andrews,Alex G Cuenca,Ramanuj DasGupta,Adam J Gehring,Dominic Grün,Martin Guilliams,Aliya Gulamhusein,Neil C Henderson,Gideon Hirschfield,Stacey S Huppert,Shalev Itzkovitz,Z Gordon Jiang,Georg M Lauer,Ian McGilvray,Krupa R Mysore,Carlos J Pirola,Gerald Quon,Mohammad Rahbari,Aviv Regev,Amanda Ricciuto,Charlotte L Scott,Ankur Sharma,Silvia Sookoian,Michelle M Tana,Sarah A Teichmann,Ludovic Vallier,Ioannis S Vlachos,Bruce Wang,Mei Zhen

{"title":"Towards a reference cell atlas of liver diversity over the human lifespan.","authors":"Sarah A Taylor,Gary D Bader,Sonya MacParland,Alan C Mullen,Tallulah Andrews,Alex G Cuenca,Ramanuj DasGupta,Adam J Gehring,Dominic Grün,Martin Guilliams,Aliya Gulamhusein,Neil C Henderson,Gideon Hirschfield,Stacey S Huppert,Shalev Itzkovitz,Z Gordon Jiang,Georg M Lauer,Ian McGilvray,Krupa R Mysore,Carlos J Pirola,Gerald Quon,Mohammad Rahbari,Aviv Regev,Amanda Ricciuto,Charlotte L Scott,Ankur Sharma,Silvia Sookoian,Michelle M Tana,Sarah A Teichmann,Ludovic Vallier,Ioannis S Vlachos,Bruce Wang,Mei Zhen","doi":"10.1038/s41575-025-01114-3","DOIUrl":"https://doi.org/10.1038/s41575-025-01114-3","url":null,"abstract":"The goal of the Human Liver Cell Atlas (HLiCA) is to create a comprehensive map that defines the normal functions of diverse liver cell types and their spatial relationships over the human lifespan. This project fits within the goals of the Human Cell Atlas to create comprehensive reference maps of all human cells as a basis for both understanding human health and diagnosing, monitoring and treating disease. Through collection of samples from diverse individuals, data integration across technologies and overcoming liver-specific challenges for experimental methods, the HLiCA will map as many cell types and states as possible in healthy human livers from individuals across all ages and many ancestries. Establishing this HLiCA of healthy livers is a critical step to begin to understand perturbations in disease. The HLiCA will be available on an open-access platform to facilitate data sharing and dissemination. We expect that creation of the HLiCA will help to lay the foundation for new research initiatives to advance our understanding of liver disease, improve methods of tissue engineering, and identify novel prognostic biomarkers and therapies to improve patient outcomes. We describe key experimental and computational challenges to overcome in building the atlas and the potential impact of the atlas on disease research.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"7 1","pages":""},"PeriodicalIF":65.1,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145283451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in liver and pancreas organoids: how far we have come and where we go next. 肝脏和胰腺类器官的进展：我们已经走了多远，下一步要去哪里？

IF 65.1 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-10-10 DOI: 10.1038/s41575-025-01116-1

Aleksandra Sljukic,Joshua Green Jenkinson,Armin Niksic,Nicole Prior,Meritxell Huch

引用次数: 0

Bezafibrate for primary biliary cholangitis: time to act on the evidence. 贝扎布特治疗原发性胆管炎：是时候采取行动了。

IF 65.1 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-10-10 DOI: 10.1038/s41575-025-01135-y

Christophe Corpechot,Maria-Carlota Londoño,Alejandra Villamil,Henriette Ytting,Atsushi Tanaka,Ulrich Beuers

引用次数: 0

WNT-β-catenin signalling in hepatocellular carcinoma: from bench to clinical trials. 肝细胞癌中WNT-β-catenin信号：从实验到临床试验

IF 65.1 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-10-09 DOI: 10.1038/s41575-025-01127-y

Brandon M Lehrich,Satdarshan P Monga

{"title":"WNT-β-catenin signalling in hepatocellular carcinoma: from bench to clinical trials.","authors":"Brandon M Lehrich,Satdarshan P Monga","doi":"10.1038/s41575-025-01127-y","DOIUrl":"https://doi.org/10.1038/s41575-025-01127-y","url":null,"abstract":"WNT-β-catenin activation is observed in around 50% of all patients with hepatocellular carcinoma (HCC), through either gain-of-function mutations in CTNNB1 (which encodes β-catenin) or loss-of-function mutations in AXIN1 or APC. Currently, first-line therapies for HCC are immune checkpoint inhibitor (ICI) combinations, and β-catenin-active HCCs have garnered increased attention due to their unique tumour immune microenvironment (TIME). This pathway is known to drive an immune-excluded TIME, but clinical investigations have provided a more nuanced perspective, with the emergence of a new 'immune-like' subclass of HCC that is paradoxically enriched for CTNNB1 mutations and has high levels of T cell infiltration. As such, patients and animal models with β-catenin activation treated with ICIs exhibit heterogeneous responses. Additionally, these tumours exhibit higher fatty acid oxidation to fuel tumour growth owing to a unique metabolic milieu shaped by zone 3 metabolism, which is a physiological function of WNT-β-catenin signalling in the liver lobule. Biomarkers to detect molecular subclasses of patients for targeted therapies are being developed. In this Review, we discuss advances in our understanding of the TIME and metabolism of β-catenin-active HCC, driven by in vitro and in vivo models and single-cell and spatial sequencing, and their implications for the treatment of a subset of HCCs using precision therapies against WNT-β-catenin signalling.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"19 1","pages":""},"PeriodicalIF":65.1,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nivolumab and ipilimumab as neoadjuvant therapy for potentially resectable HCC. Nivolumab和ipilimumab作为潜在可切除HCC的新辅助治疗。

IF 65.1 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-10-06 DOI: 10.1038/s41575-025-01136-x

Jordan Hindson

引用次数: 0

Aspirin and recurrence of PI3K-mutated CRC. 阿司匹林与pi3k突变结直肠癌复发的关系。

IF 65.1 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-10-06 DOI: 10.1038/s41575-025-01137-w

Jordan Hindson

引用次数: 0

Submucosal electronics for long-term in situ diagnosis and therapeutics of gastrointestinal diseases. 粘膜下电子学用于胃肠道疾病的长期原位诊断和治疗。

IF 65.1 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-10-06 DOI: 10.1038/s41575-025-01130-3

Chong Zhang,Kai Fung Chan,Chengfeng Pan,Xianfeng Xia,Philip Wai Yan Chiu

引用次数: 0

A neurobiotic sense curbs feeding: a new frontier in gut-brain communication. 神经生物的感觉控制进食：肠脑交流的新前沿。

IF 65.1 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-10-02 DOI: 10.1038/s41575-025-01126-z

Rajan Singh

引用次数: 0

Maternal gut microbiome in early pregnancy: predictor of preterm birth? 妊娠早期孕妇肠道微生物组：早产的预测因子？

IF 65.1 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-09-29 DOI: 10.1038/s41575-025-01131-2

Katrina Ray

引用次数: 0

Interaction of inflammation and portal hypertension in cirrhosis progression. 肝硬化进展中炎症和门静脉高压的相互作用。

IF 65.1 1区医学

Nature Reviews Gastroenterology &Hepatology Pub Date : 2025-09-29 DOI: 10.1038/s41575-025-01107-2

Dalila Costa,Jonel Trebicka,Cristina Ripoll,Richard Moreau,Rajiv Jalan,Thomas Reiberger

{"title":"Interaction of inflammation and portal hypertension in cirrhosis progression.","authors":"Dalila Costa,Jonel Trebicka,Cristina Ripoll,Richard Moreau,Rajiv Jalan,Thomas Reiberger","doi":"10.1038/s41575-025-01107-2","DOIUrl":"https://doi.org/10.1038/s41575-025-01107-2","url":null,"abstract":"Decompensated cirrhosis describes an advanced clinical stage with clinical complications, such as ascites, variceal bleeding or hepatic encephalopathy, associated with considerable mortality. Portal hypertension is the main risk factor for developing decompensation in patients with compensated cirrhosis, whereas systemic inflammation is the key driving force for organ failure, that is, for acute-on-chronic liver failure in later stages of cirrhosis. As portal hypertension and systemic inflammation coexist in patients with cirrhosis, an improved understanding of their interaction and dynamic role in distinct stages of cirrhosis is an important step forward towards the development of urgently needed therapeutic interventions. Based on emerging evidence from clinical and translational studies, a novel concept of different predominant pathomechanisms of decompensated cirrhosis is presented, which includes portal hypertension-predominant, systemic inflammmation-predominant and mixed portal hypertension-systemic inflammation phenotypes. A comprehensive set of biomarkers and surrogates of portal hypertension and systemic inflammation might assist clinicians in identifying a predominance of one over the other cirrhosis phenotype. As survival rates of patients with decompensated cirrhosis have remained detrimental without liver transplantation over the past decades, future studies should build on this knowledge to develop effective portal hypertension and systemic inflammation-directed therapies for this underserved population.","PeriodicalId":18793,"journal":{"name":"Nature Reviews Gastroenterology &Hepatology","volume":"7 1","pages":""},"PeriodicalIF":65.1,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0